LOGIN
Effect of Bamlanivimab (LY-CoV555) Antibody Treatment on Viral Load & Clinical Outcomes for COVID-19
November 2020
Effect of Bamlanivimab (LY-CoV555) Antibody Treatment on Viral Load & Clinical Outcomes for COVID-19
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
N Engl J Med. 2020 Oct 28.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Four hundred and fifty two patients who tested positive for coronavirus disease 19 (COVID19) were randomized to receive a single intravenous infusion of LY-CoV555, at a dose of 700mg, 2800mg, or 7000mg, or placebo, for the reduction of viral load and amelioration of symptoms. The primary outcome of interest was the change from baseline in viral load at 11 days follow up. Secondary outcomes of inte...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.